Close

bluebird bio (BLUE) Opens Phase 3 Study of LentiGlobin in Patients with Transfusion-Dependent Beta-Thalassemia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/24/2024

1. TSLA
2. ENPH
3. TXN
4. SPOT
5. V
6. KMB
7. FI
8. BA
9. PNR
10. MSCI


Go back to bluebird bio (BLUE) Opens Phase 3 Study of LentiGlobin in Patients with Transfusion-Dependent Beta-Thalassemia
BLUEBIRD BIO (NASDAQ: BLUE) Delayed: 0.97 --0 (-0%)
Previous Close $0.97    52 Week High $95.28 
Open $0.97    52 Week Low $35.37 
Day High $0.97    P/E N/A 
Day Low $0.97    EPS $-1.81 
Volume 5,694